The North American Neuromodulation Society (NANS) has joined seven national medical specialty societies in signing a joint letter urging Blue Cross Blue Shield of Illinois, Montana, New Mexico, Oklahoma, and Texas—as well as the Health Care Services Corporation—to revise their draft policy on implantable peripheral nerve stimulation (PNS) for chronic pain.

NANS was alerted that several insurers, including Cigna, eviCore, Excellus, Humana, and UPMC, adopted policies calling closed-loop SCS experimental, investigational, and/or unproven.